½ÃÀ庸°í¼­
»óǰÄÚµå
1708215

Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)

Polynucleotides Injectables Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 131 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ ½ÃÀåÀº 2024³â¿¡ 1¾ï 2,780¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2025-2034³â¿¡ CAGR 15.3%·Î È®´ëÇϸç, °­·ÂÇÑ ¼ºÀåÀ» ´Þ¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¤Á¦µÈ DNA Á¶°¢À» ÇÔÀ¯ÇÑ ÀÌ ÁÖ»ç Ä¡·á´Â ÁÖ·Î Àç»ý ÀÇÇÐ ¹× ¹Ì¿ë ¿ëµµ·Î »ç¿ëµË´Ï´Ù. Á¶Á÷ Àç»ýÀ» ÃËÁøÇϰí, ¿°ÁõÀ» ¾ïÁ¦Çϰí, ¼öºÐ °ø±ÞÀ» °­È­Çϸç, ÇǺΠź·ÂÀ» °³¼±Çϰí, Á¶Á÷ ȸº¹À» ÃËÁøÇϰí, °üÀý °Ç°­À» Áö¿øÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ ¸¹Àº ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ºñħ½ÀÀû Ä¡·á¹ý¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ °ü½É Áõ°¡¿Í ÀÔÁõµÈ È¿°ú·Î ÀÎÇØ °ßÀηÂÀ» ¾ò°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Ã·´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ Á¤Ã¥ ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀεµ ½ÃÀå ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ÀÓ»ó ¹× ¹Ì¿ë ºÐ¾ß¿¡¼­ Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦ µµÀÔ¿¡ À¯¸®ÇÑ È¯°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.

Polynucleotides Injectables Market-IMG1

´Ù¾çÇÑ ¿ëµµ Áß ¾È°ú Ä¡·á´Â 2024³â±îÁö ½ÃÀå ¸ÅÃâÀÇ 62.3%¸¦ Â÷ÁöÇϸç, ±× ¼ºÀå¼¼´Â °è¼ÓµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÁÖ»çÁ¦´Â Äݶó°Õ »ý¼ºÀ» ÀÚ±ØÇÏ¿© ÇǺΠź·ÂÀ» Áõ°¡½ÃÄÑ ´« ¹Ø ²¨Áü, ÁÖ¸§, ´ÙÅ©¼­Å¬°ú °°Àº ¹Ì¿ë ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ ¸Å¿ì È¿°úÀûÀÔ´Ï´Ù. ºñħ½ÀÀû ½Ã¼úÀÇ Àαâ·Î ÀÎÇØ ´«°¡ÀÇ ¹Î°¨ÇÑ ÇǺθ¦ Àþ¾îÁö°Ô ÇϰíÀÚ ÇÏ´Â »ç¶÷µé¿¡°Ô ¼±È£µÇ´Â ºñħ½ÀÀû ½Ã¼ú·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ¿¬µµ 2024³â
¿¹Ãø¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 1¾ï 2,780¸¸ ´Þ·¯
¿¹»ó ±Ý¾× 5¾ï 2,570¸¸ ´Þ·¯
CAGR 15.3%

¸ÞµðÄà ½ºÆÄ´Â ½ÃÀåÀÇ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌµé ½ºÆÄ´Â Àüü ½ÃÀå Á¡À¯À²ÀÇ 48.5%¸¦ Â÷ÁöÇϸç 2024³â¿¡´Â 6,200¸¸ ´Þ·¯ÀÇ ¸ÅÃâÀ» âÃâÇß½À´Ï´Ù. ºñ¼ö¼úÀû ¹Ì¿ë Ä¡·áÀÇ ÀαⰡ ³ô¾ÆÁü¿¡ µû¶ó ¼ÒºñÀÚµéÀº ÆíÀǼº, °æÁ¦¼º, °³ÀÎ ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ ÀÇ·á¿ë ½ºÆÄ¸¦ Á¡Á¡ ´õ ¸¹ÀÌ ¼±ÅÃÇϰí ÀÖ½À´Ï´Ù. ȸº¹ ½Ã°£ÀÌ Âª°í ÀÚ¿¬½º·¯¿î °á°ú¸¦ ¼±È£ÇÏ´Â °æÇâÀº ÀÌ·¯ÇÑ ½Ã¼³¿¡¼­ Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÏ¿© 2024³â¿¡´Â ¸ÅÃâ¾×ÀÌ 5,300¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °¡Ã³ºÐ ¼ÒµæÀÌ ³ô°í °í±Þ ¼¿ÇÁ Äɾî Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ôÀº ¹Ì±¹Àº 2023³â 4,060¸¸ ´Þ·¯ÀÇ ±â¿©¸¦ ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ÒºñÀÚµéÀº ºñħ½ÀÀû ½Ã¼ú°ú ¹Ì¿ëÀû °Ç°­À» Á¡Á¡ ´õ ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ½ÃÀå È®´ë¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ·¯ÇÑ ÁÖ»çÁ¦°¡ ÀÇ·á ¹× ¹Ì¿ë ¸ñÀûÀ¸·Î ´õ ³Î¸® »ç¿ëµÊ¿¡ µû¶ó ±× ½ÃÀåÀº ´Ù¾çÇÑ Áö¿ª, ƯÈ÷ ¸ÞµðÄà ½ºÆÄ ¹× ¾È°ú Ä¡·á ¿ëµµ¿¡¼­ ²ÙÁØÈ÷ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¹Ì¿ë ¹× Àç»ý ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡
      • Æú¸®´ºÅ¬·¹¿ÀƼµå ÁÖ»ç ±â¼úÀÇ Áøº¸
      • ¹Ì¿ë ÇǺΠġ·á¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀǽÄÀÇ Çâ»ó
      • À¯¸®ÇÑ ±ÔÁ¦±â°üÀÇ ½ÂÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ºÎÀÛ¿ë°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á
      • °íºñ¿ë°ú ÇÑÁ¤µÈ ¾×¼¼½º¼º
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • °¸ ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¾ÖÇø®ÄÉÀ̼Ǻ°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ´«
  • ÀÔ¼ú
  • À̸¶
  • Åμ± ¹× ±¤´ë»À
  • ±âŸ ¿ëµµ

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ¸ÞµðÄà ½ºÆÄ
  • ¿¡½ºÅׯ½ ¼¾ÅÍ
  • º´¿ø

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®

Á¦8Àå ±â¾÷ °³¿ä

  • AMEELA
  • BR Pharm
  • Croma Pharma
  • DermaFocus
  • Fox Pharma
  • Genoss
  • Lkc Pharma
  • Mastelli
  • Pluryal
  • Promoitalia Laboratories
KSA 25.05.15

The Global Polynucleotides Injectables Market, valued at USD 127.8 million in 2024, is projected to experience robust growth, expanding at a CAGR of 15.3% between 2025 and 2034. These injectable treatments, which contain purified DNA fragments, are primarily used in regenerative medicine and aesthetic applications. Their ability to promote tissue regeneration, reduce inflammation, and enhance hydration makes them highly sought after for improving skin elasticity, encouraging tissue repair, and supporting joint health. The market is gaining traction due to increasing consumer interest in non-invasive procedures and their proven benefits, driving demand for these advanced treatments. Government policies and regulatory approvals also play a critical role in propelling market growth, creating a favorable environment for the adoption of polynucleotide injectables in both clinical and aesthetic settings.

Polynucleotides Injectables Market - IMG1

Among the various applications, eye treatment has emerged as the dominant segment in the market. By 2024, this segment accounted for 62.3% of market revenue, and its growth is expected to continue. The injectables are highly effective in addressing cosmetic concerns such as under-eye hollows, wrinkles, and dark circles by stimulating collagen production and enhancing skin elasticity. The popularity of these treatments in non-invasive procedures has positioned them as a preferred option for individuals looking to rejuvenate the sensitive skin around the eyes.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$127.8 Million
Forecast Value$525.7 Million
CAGR15.3%

Medical spas have become a major driving force in the market, contributing significantly to its expansion. These spas accounted for 48.5% of the total market share, generating USD 62 million in 2024. As non-surgical aesthetic treatments gain popularity, consumers increasingly choose medical spas for their convenience, affordability, and ability to provide personalized solutions. The preference for minimal recovery time and natural-looking results further boosts the demand for polynucleotide injectables in these establishments.

Geographically, North America is expected to lead the market growth, with revenues projected to reach USD 53 million in 2024. The U.S. is expected to dominate, contributing USD 40.6 million in 2023, driven by a high disposable income and a growing trend toward premium self-care treatments. As consumers in the region increasingly prioritize non-invasive procedures and aesthetic wellness, the demand for polynucleotide injectables is set to rise, further fueling market expansion.

As these injectables become more widely used for both medical and cosmetic purposes, their market is anticipated to continue growing steadily across various regions, particularly in medical spas and eye treatment applications.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing demand for aesthetic and regenerative solutions
      • 3.2.1.2 Advancements in polynucleotide injectable technologies
      • 3.2.1.3 Growing consumer awareness about aesthetic skin treatments
      • 3.2.1.4 Favorable regulatory approvals
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Side effects and safety concerns
      • 3.2.2.2 High costs and limited accessibility
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Eyes
  • 5.3 Lips
  • 5.4 Forehead
  • 5.5 Jawline and cheekbones
  • 5.6 Other applications

Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Medical spas
  • 6.3 Aesthetic and cosmetic centers
  • 6.4 Hospitals

Chapter 7 Market Estimates and Forecast, By Region, 2021- 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 India
    • 7.4.3 Japan
    • 7.4.4 Australia
    • 7.4.5 South Korea
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
  • 7.6 Middle East and Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 South Africa
    • 7.6.3 UAE

Chapter 8 Company Profiles

  • 8.1 AMEELA
  • 8.2 BR Pharm
  • 8.3 Croma Pharma
  • 8.4 DermaFocus
  • 8.5 Fox Pharma
  • 8.6 Genoss
  • 8.7 Lkc Pharma
  • 8.8 Mastelli
  • 8.9 Pluryal
  • 8.10 Promoitalia Laboratories
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦